XML 78 R68.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Segment Reporting - Sales from Products (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 14,959 | $ 13,154 | $ 45,453 | $ 35,183
Revenue related to the sale of the marketing rights |  |  | 156 | 191
U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,322 | 6,276 | 20,927 | 16,166
Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,637 | 6,878 | 24,526 | 19,017
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 14,334 | 12,913 | 44,146 | 35,021
Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,095 | 6,137 | 20,544 | 15,974
Operating Segments | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,239 | 6,777 | 23,601 | 19,047
Corporate, Non-Segment |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 625 | 241 | 1,307 | 162
Corporate, Non-Segment | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 227 | 139 | 383 | 192
Corporate, Non-Segment | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 398 | 101 | 925 | (30)
Pharmaceutical | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 12,963 | 11,496 | 39,826 | 30,714
Pharmaceutical | Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,620 | 5,670 | 19,119 | 14,611
Pharmaceutical | Operating Segments | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,343 | 5,826 | 20,707 | 16,103
Pharmaceutical | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,426 | 4,534 | 15,487 | 12,609
Pharmaceutical | Operating Segments | Keytruda | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3,331 | 2,580 | 9,307 | 7,108
Pharmaceutical | Operating Segments | Keytruda | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,095 | 1,954 | 6,180 | 5,501
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 284 | 246 | 825 | 721
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 144 | 129 | 427 | 371
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 140 | 117 | 397 | 350
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 202 | 188 | 660 | 498
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 142 | 114 | 426 | 287
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 60 | 74 | 235 | 211
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 39 | 0 | 124 | 0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 32 | 0 | 87 | 0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7 | 0 | 37 | 0
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,294 | 1,993 | 5,428 | 4,144
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 957 | 839 | 1,803 | 1,605
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,337 | 1,154 | 3,624 | 2,539
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 668 | 661 | 1,716 | 1,626
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 532 | 537 | 1,337 | 1,255
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 136 | 125 | 379 | 371
Pharmaceutical | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 256 | 227 | 644 | 593
Pharmaceutical | Operating Segments | RotaTeq | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 154 | 135 | 427 | 364
Pharmaceutical | Operating Segments | RotaTeq | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 102 | 92 | 218 | 229
Pharmaceutical | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 131 | 277 | 457 | 600
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 68 | 181 | 280 | 354
Pharmaceutical | Operating Segments | Pneumovax 23 | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 97 | 177 | 247
Pharmaceutical | Operating Segments | Vaqta |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 64 | 48 | 134 | 138
Pharmaceutical | Operating Segments | Vaqta | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 27 | 32 | 72 | 80
Pharmaceutical | Operating Segments | Vaqta | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 36 | 16 | 62 | 58
Pharmaceutical | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 423 | 369 | 1,244 | 1,096
Pharmaceutical | Operating Segments | Bridion | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 233 | 181 | 665 | 545
Pharmaceutical | Operating Segments | Bridion | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 190 | 188 | 579 | 551
Pharmaceutical | Operating Segments | Prevymis |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 114 | 96 | 310 | 270
Pharmaceutical | Operating Segments | Prevymis | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 49 | 39 | 136 | 111
Pharmaceutical | Operating Segments | Prevymis | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 64 | 57 | 174 | 159
Pharmaceutical | Operating Segments | Dificid |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 77 | 54 | 196 | 115
Pharmaceutical | Operating Segments | Dificid | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 72 | 52 | 184 | 108
Pharmaceutical | Operating Segments | Dificid | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6 | 2 | 12 | 7
Pharmaceutical | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 70 | 185 | 194
Pharmaceutical | Operating Segments | Primaxin | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 1 | 0
Pharmaceutical | Operating Segments | Primaxin | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 69 | 185 | 194
Pharmaceutical | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 62 | 64 | 180 | 197
Pharmaceutical | Operating Segments | Noxafil | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 13 | 19 | 39 | 48
Pharmaceutical | Operating Segments | Noxafil | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 49 | 45 | 141 | 149
Pharmaceutical | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 50 | 53 | 148 | 157
Pharmaceutical | Operating Segments | Invanz | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2 | (2) | 4 | (2)
Pharmaceutical | Operating Segments | Invanz | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 48 | 55 | 144 | 159
Pharmaceutical | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 43 | 56 | 138 | 168
Pharmaceutical | Operating Segments | Cancidas | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1 | 1 | 5 | 4
Pharmaceutical | Operating Segments | Cancidas | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 42 | 56 | 133 | 164
Pharmaceutical | Operating Segments | Zerbaxa |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 43 | (2) | 120 | (11)
Pharmaceutical | Operating Segments | Zerbaxa | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 24 | (1) | 64 | (5)
Pharmaceutical | Operating Segments | Zerbaxa | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 19 | (1) | 55 | (6)
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 88 | 100 | 258 | 248
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 85 | 73 | 244 | 222
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3 | 27 | 14 | 26
Pharmaceutical | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 57 | 59 | 181 | 188
Pharmaceutical | Operating Segments | Adempas | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Adempas | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 57 | 59 | 181 | 188
Pharmaceutical | Operating Segments | Lagevrio |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 436 | 0 | 4,859 | 0
Pharmaceutical | Operating Segments | Lagevrio | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 1,523 | 0
Pharmaceutical | Operating Segments | Lagevrio | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 436 | 0 | 3,336 | 0
Pharmaceutical | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 161 | 189 | 466 | 590
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 68 | 77 | 196 | 222
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 93 | 112 | 270 | 368
Pharmaceutical | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 62 | 81 | 199 | 238
Pharmaceutical | Operating Segments | Belsomra | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 20 | 23 | 60 | 56
Pharmaceutical | Operating Segments | Belsomra | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 42 | 58 | 139 | 183
Pharmaceutical | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 173 | 203 | 540 | 619
Pharmaceutical | Operating Segments | Simponi | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Simponi | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 173 | 203 | 540 | 619
Pharmaceutical | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 49 | 73 | 163 | 233
Pharmaceutical | Operating Segments | Remicade | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Remicade | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 49 | 73 | 163 | 233
Pharmaceutical | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 717 | 852 | 2,252 | 2,445
Pharmaceutical | Operating Segments | Januvia | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 332 | 365 | 958 | 997
Pharmaceutical | Operating Segments | Januvia | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 385 | 487 | 1,294 | 1,448
Pharmaceutical | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 417 | 487 | 1,347 | 1,449
Pharmaceutical | Operating Segments | Janumet | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 90 | 86 | 258 | 244
Pharmaceutical | Operating Segments | Janumet | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 327 | 401 | 1,089 | 1,205
Pharmaceutical | Operating Segments | Other pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 564 | 518 | 1,565 | 1,589
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 244 | 210 | 616 | 637
Pharmaceutical | Operating Segments | Other pharmaceutical | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 321 | 306 | 949 | 950
Animal Health | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,371 | 1,417 | 4,320 | 4,307
Animal Health | Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 475 | 467 | 1,425 | 1,363
Animal Health | Operating Segments | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 896 | 951 | 2,894 | 2,944
Animal Health | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 829 | 864 | 2,486 | 2,503
Animal Health | Operating Segments | Livestock | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 186 | 190 | 521 | 508
Animal Health | Operating Segments | Livestock | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 643 | 675 | 1,965 | 1,996
Animal Health | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 542 | 553 | 1,834 | 1,804
Animal Health | Operating Segments | Companion Animals | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 289 | 277 | 904 | 855
Animal Health | Operating Segments | Companion Animals | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 253 | $ 276 | $ 929 | $ 948

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DificidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LagevrioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |